MSF Scientific Days

9-10 May 2019
London, UK

  • Fabiana Barreira, Chagas Senior Clinical Manager – presentation of the BENDITA trial for Chagas disease
  • Nathalie Strub-Wourgaft, Director NTDs – presentation on registration steps for the new all oral sleeping sickness treatment

R&D Portfolio Update February 2019: DNDi Sleeping sickness programme

Fexinidazole, the first all-oral treatment for both stages of HAT caused by T.b gambiense and DNDi’s first new chemical entity, was recommended by the European Medicines Agency in November and registered in Democratic Republic of Congo (DRC) in December 2018. The Phase II/III study on acoziborole opened new clinical sites in DRC and Guinea.

ISNTD Festival 2019

11-12 March 2019
London, United Kingdom

  • Submission of the film “A doctor’s dream” to the ISNTD Festival Awards

Le fexinidazole, premier traitement entièrement par voie orale contre la maladie du sommeil, approuvé en République Démocratique du Congo

Paris/Genève, 30 Janvier 2019

La République Démocratique du Congo (RDC) a délivré une autorisation de mise sur le marché au fexinidazole pour le traitement de la trypanosomiase humaine africaine (THA) ou maladie du sommeil causée par le parasite Trypanosoma brucei gambiense. Cette approbation ouvre la voie à la distribution du  fexinidazole, cette année, dans les pays où la maladie du sommeil est endémique, sachant qu’une autre soumission réglementaire est également prévue en Ouganda.

Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo

Paris/Geneva – 30 January 2019
Marketing authorization of fexinidazole for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis, more commonly known as sleeping sickness, has been granted in the Democratic Republic of Congo (DRC). This approval paves the way for the distribution of fexinidazole in endemic countries this year, with another submission planned in Uganda.